| 13.29 0 (0%) | 11-30 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 15.61 | 1-year : | 15.88 |
| Resists | First : | 13.37 | Second : | 13.6 |
| Pivot price | 13.24  |
|||
| Supports | First : | 13 | Second : | 10.81 |
| MAs | MA(5) : | 13.28 | MA(20) : | 13.28  |
| MA(100) : | 7.75 |
MA(250) : | 6 |
|
| MACD | MACD : | 0.3 |
Signal : | 0.5 |
| %K %D | K(14,3) : | 64.2 |
D(3) : | 54.5 |
| RSI | RSI(14): 71.3 | |||
| 52-week | High : | 13.6 | Low : | 2.31 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ AKUS ] has closed below upper band by 30.6%. Bollinger Bands are 91.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 23 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 13.32 - 13.39 | 13.39 - 13.44 |
| Low: | 13.1 - 13.2 | 13.2 - 13.27 |
| Close: | 13.16 - 13.3 | 13.3 - 13.41 |
Akouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. The company is also developing AK-CLRN1 for the auditory manifestations of Usher syndrome 3A, or USH3A; and AK-antiVEGF for vestibular schwannoma. In addition, its precision genetic medicine platform addresses hearing loss related to genes needed for supporting cell function. The company was incorporated in 2016 and is based in Boston, Massachusetts.
Thu, 01 Dec 2022
Lilly Completes Acquisition of Akouos Expanding Efforts to Help People with Genetic Diseases - Eli Lilly and Company
Wed, 30 Nov 2022
Lilly and Akouos Announce Expiration of Akouos Tender Offer - PR Newswire
Tue, 18 Oct 2022
Lilly’s message is loud and clear: Akouos’ AAV hearing loss therapy is worthwhile - BioWorld MedTech
Tue, 18 Oct 2022
Eli Lilly to acquire hearing loss startup for up to $618M - The Business Journals
Tue, 18 Oct 2022
Eli Lilly to buy gene therapy company Akouos for $487 mln - Reuters
Tue, 18 Oct 2022
Lilly to Acquire Akouos to Discover and Develop Treatments for Hearing Loss | Eli Lilly and Company - Eli Lilly and Company
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 37 (M) |
| Shares Float | 19 (M) |
| Held by Insiders | 1.1 (%) |
| Held by Institutions | 104.8 (%) |
| Shares Short | 828 (K) |
| Shares Short P.Month | 2,280 (K) |
| EPS | -2.83 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.9 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -22.3 % |
| Return on Equity (ttm) | -42.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.45 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -74 (M) |
| Levered Free Cash Flow | -60 (M) |
| PE Ratio | -4.7 |
| PEG Ratio | -0.2 |
| Price to Book value | 2.71 |
| Price to Sales | 0 |
| Price to Cash Flow | -6.63 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|